At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 13, 2026 at 06:50 ET
ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the posterior segment (NIU-PS), meeting both co-primary endpoints with statistical significance. The results support the drug's safety and efficacy in a real-world setting, potentially boosting commercial uptake.
- SYNCHRONICITY trial met co-primary endpoints: mean change in BCVA (+3.6 letters, p<0.0077) and CST (-157.5 microns, p<0.0001) at 6 months.
- Safety profile consistent with prior ILUVIEN trials; 29% treatment-related TEAEs, most common ocular hypertension (6%) and cataract (5%).
- ILUVIEN already FDA-approved for DME (2014) and expanded for chronic NIU-PS (2025); this Phase 4 data adds real-world evidence.
- Detailed results to be presented at medical conferences in Q4 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access